Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 10/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 10/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6652063 | 0.87 | DRD2 (0.48) | OPRM1CHRM2CHRM3UBE2MDCUN1D1 | |
| SCHEMBL6652103 | 0.87 | UBE2M (0.47) | OPRM1CHRM2CHRM3UBE2MDCUN1D1 | |
| SCHEMBL6651283 | 0.87 | OPRM1 (0.41) | OPRM1CHRM2CHRM3MEN1KMT2A | |
| SCHEMBL6656007 | 0.85 | OPRM1 (0.46) | OPRM1CHRM2CHRM3UBE2MDCUN1D1 | |
| SCHEMBL6655097 | 0.83 | OPRM1 (0.50) | LMNAOPRM1CHRM2CHRM3UBE2M | |
| SCHEMBL6656589 | 0.83 | OPRM1 (0.49) | LMNAOPRM1CHRM2CHRM3UBE2M | |
| SCHEMBL6656905 | 0.82 | CTSS (0.47) | OPRM1UBE2MDCUN1D1 | |
| SCHEMBL6658372 | 0.82 | CTSS (0.55) | UBE2MDCUN1D1 | |
| SCHEMBL6654132 | 0.81 | MEN1 (0.40) | LMNAOPRM1CHRM2CHRM3KDM4E | |
| SCHEMBL6652554 | 0.80 | CHRM2 (0.50) | LMNAOPRM1CHRM2CHRM3UBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1417202-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-12 | — | — | EP | claimed |
| US-20030069276-A1 | Amino piperidine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | US | claimed |
| WO-2002079186-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069276-A1 | Amino piperidine derivatives | CCR5, CCR2, CXCR4 | LMNA 4529/4885OPRM1 84/4885CHRM2 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.